Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CTOR

Citius Oncology Inc

Last Close
Dec 03 04:00PM ET
1.46
Dollar change
+0.44
Percentage change
43.14
%
Index- P/E5.96 EPS (ttm)0.24 Insider Own97.47% Shs Outstand2.34M Perf Week71.74%
Market Cap104.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.35M Perf Month28.07%
Income1.93M PEG- EPS next Q-0.06 Inst Own0.40% Short Float8.50% Perf Quarter-15.61%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.14 Perf Half Y-86.86%
Book/sh-0.46 P/B- EPS next Y- ROA3.25% Short Interest0.03M Perf Year-85.98%
Cash/sh0.00 P/C- EPS next 5Y- ROE3.35% 52W Range0.85 - 49.00 Perf YTD-86.65%
Dividend Est.- P/FCF- EPS past 5Y- ROI4.19% 52W High-97.02% Beta-0.31
Dividend TTM- Quick Ratio0.01 Sales past 5Y0.00% Gross Margin- 52W Low71.76% ATR (14)0.25
Dividend Ex-Date- Current Ratio0.01 EPS Y/Y TTM- Oper. Margin- RSI (14)61.74 Volatility38.54% 18.85%
Employees- Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q-44.59% Payout0.00% Rel Volume473.90 Prev Close1.02
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsNov 27 Avg Volume214.36K Price1.46
SMA2033.52% SMA5026.12% SMA200-81.00% Trades Volume101,583,996 Change43.14%
Date Action Analyst Rating Change Price Target Change
Nov-27-24Initiated Maxim Group Buy $3
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.